Strontium ranelate


Concise Prescribing Info
Indications/Uses
Postmenopausal osteoporosis.
Dosage/Direction for Use
Adult : PO 2 g/day.
Dosage Details
Oral
Postmenopausal osteoporosis
Adult: 2 g daily.
Elderly: No dosage adjustment needed.
Renal Impairment
No dosage adjustment needed.
Hepatic Impairment
No dosage adjustment needed.
Administration
Should be taken on an empty stomach. Take between meals, preferably at bedtime at least 2 hr after food, milk, milk products or Ca supplements. Mix only w/ plain water & drink immediately.
Contraindications
Patients w/ current or previous venous thromboembolic events including deep vein thrombosis and pulmonary embolism; temporary or permanent immobilisation due to post-surgical recovery or prolonged bed rest; current or history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease; uncontrolled HTN. Lactation.
Special Precautions
Renal impairment. Pregnancy.
Adverse Reactions
Headache, GI disturbances, eczema, dermatitis; memory loss, consciousness disturbances, seizures, pyrexia, peripheral oedema, confusion, bronchial hyperreactivity. Angioedema, rash, urticaria, pruritus. Transient increases in creatine kinase activity (reversible).
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome, and drug rash w/ eosinophilia and systemic symptoms.
Drug Interactions
May reduce the absorption of oral tetracycline and quinolone antibiotics. Medicinal products containing Ca may reduce strontium ranelate bioavailability.
Food Interaction
Food, milk and derivative products containing Ca may reduce strontium ranelate bioavailability.
Lab Interference
May interfere w/ determination of serum and urinary Ca.
Action
Description: Strontium ranelate stimulates bone formation, osteoblast precursor replication and collagen synthesis. Decreasing osteoclast differentiation and resorbing activity, it reduces bone resorption resulting in a rebalance of bone turnover in favour of bone formation.
Pharmacokinetics:
Absorption: Food, milk and derivative products containing Ca may reduce bioavailability by approx 60-70%. Absolute bioavailability: Approx 25%. Time to peak plasma concentration: 3-5 hr.
Distribution: Volume of distribution: 1 L/kg. Plasma protein binding: Low (25%).
Metabolism: Not metabolised.
Excretion: Via kidneys and GI tract. Half-life: Approx 60 hr.
Disclaimer: This information is independently developed by MIMS based on Strontium ranelate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Protaxos
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in